On October 6, 2025, Gilead Sciences, Inc. reported that it has reached settlement agreements with Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd. regarding patent litigations for Biktarvy, ensuring no generic versions will enter the market before April 1, 2036.